GSK Reports Topline Results from the P-III Trial of Arexvy Co-Administered with Shingrix
Shots:
- GSK highlighted topline data from P-III study of Arexvy (RSV vaccine) & Shingrix (zoster vaccine) in adults (≥50yrs.) at the European Geriatric Medicine Society Congress 2024 in Valencia, Spain
- The P-III trial evaluated the non-inferiority of co-administering GSK’s Arexvy and Shingrix vaccines vs separate administration among adults (n=530; ≥50yrs.), in ratio 1:1
- Study demonstrated non-inferior immune responses and good tolerability with an acceptable reactogenicity & safety, with common AEs being injection site pain, fatigue & myalgia. Data will be submitted to the US FDA, EMA & other agencies for review
Ref: Businesswire | Image: GSK
Related News:- GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
